MetaVia Inc. (MTVA): R&D Expense
$6.80M
Year ended 2025-12-31
$7.73M
Trailing 12 months to 2026-06-30
+34.8%
3-year compound annual growth
+8.5%
5-year compound annual growth
+5.5%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.80M | -68.4% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $21.55M | +135.3% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $9.16M | +229.7% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $2.78M | -57.6% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $6.55M | +44.5% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $4.53M | -14.9% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $5.32M | +5.1% | 2021-04-15, From 2019-01-01 |
| 2018-12-31 | $5.07M | -77.7% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $22.69M | +159.6% | 2019-03-18, From 2017-01-01 |
| 2016-12-31 | $8.74M | +119.0% | 2019-03-18, From 2016-01-01 |
| 2015-12-31 | $3.99M | n/m | 2018-03-20, From 2015-01-01 |
| 2014-12-31 | $52.0K | n/a | 2017-03-21, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| MetaVia Inc. (MTVA) | 2025-12-31 | $6.80M | -68.4% |
| Mira Pharmaceuticals, Inc. (MIRA) | 2025-12-31 | $1.72M | -48.0% |
| Decoy Therapeutics Inc. (DCOY) | 2025-12-31 | $368.2K | -52.2% |
| Lantern Pharma Inc. (LTRN) | 2025-12-31 | $11.51M | -28.6% |
| NewcelX Ltd. (NCEL) | 2025-12-31 | $1.13M | +13.5% |
| Curanex Pharmaceuticals Inc (CURX) | 2025-12-31 | $2.99M | n/a |
| Revelation Biosciences, Inc. (REVB) | 2025-12-31 | $4.06M | +14.5% |
| Traws Pharma, Inc. (TRAW) | 2025-12-31 | $12.14M | -5.5% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | 2025-12-31 | $4.05M | +12.0% |
Compare MTVA, MIRA, DCOY, LTRN side by side · Screen every company in Pharmaceutical Preparations ↗